#Germany #Oberkochen #AACR2026 #Mindpeak #Revolune

Introduction

The integration of innovative technologies in healthcare and life sciences is a vital step forward in expediting research and clinical outcomes. At the 2026 Annual Meeting of the American Association for Cancer Research (AACR), Revolune GmbH, a pioneering life sciences company, will showcase an integrated workflow for multiplex immunofluorescence in collaboration with MindPeak, a leader in AI-supported pathology analysis. This partnership marks a significant advancement in the field of spatial biology, highlighting the synergy between refined reagents and advanced imaging solutions.

What is Multiplex Immunofluorescence?

Multiplex immunofluorescence (mIF) is a powerful technique used to analyze multiple biomarkers within a single tissue sample, offering insights into tumor biology and immune interactions. As research in cancer biology advances, the demand for efficient, user-friendly workflows in multiplexing has become paramount. Nonetheless, existing multiplex workflows often face challenges due to their complexity and scalability issues.

The Integrated Workflow Introduction

At AACR 2026, Revolune and MindPeak will unveil their novel approach that seeks to demystify these complex processes. By blending Revolune’s sophisticated mIF reagents with MindPeak’s cutting-edge image analysis solutions, they aim to facilitate the meticulous journey of researchers—from staining tissue samples to extracting meaningful biological insights efficiently.

Florian Leiss, CEO of Revolune, emphasizes the importance of reliable experimental workflows and data evaluation in spatial biology. He states, “By merging our multiplex IF technology with the robust AI capabilities of MindPeak, we are simplifying the pathway from tissue sample to actionable spatial insights.” This innovative integration aims to enhance the research paradigm for scientists working in cancer research and biomarker discovery.

Enhancements through AI-Driven Analysis

MindPeak’s AI-enhanced pathology software offers automated analysis of multiplex image data, not only improving the quantification of biomarkers but also assisting in the spatial interpretation of complex tissue samples. Felix Faber, CEO of MindPeak, expresses excitement about the collaboration, stating, “We are thrilled to partner with Revolune to support researchers working with multiplex tissue data. Together, we aim to overcome the barriers that slow the adoption of workflows in spatial biology.”

What to Expect at AACR 2026

Participants at AACR 2026 can gain insight into this integrated workflow and engage in discussions about how combined staining and analysis solutions can bolster translational cancer research and biomarker discovery. Visitors are encouraged to stop by the Revolune and MindPeak booth (#1660) to learn more about simplifying processes in spatial biology through combined multiplex staining and AI-driven analysis.

Company Backgrounds

Revolune is dedicated to advancing spatial biology by providing optimized solutions for multiplex immunofluorescence that are as accessible as immunohistochemistry (IHC). By focusing on clarity, speed, and reliability in their reagents, the company enables researchers to derive critical biological insights from complex tissue systems. Its goal is to offer dependable multiplex workflows that promote translational and biopharmaceutical research. For more information, visit Revolune.

MindPeak, established in 2018, is a forefront company in AI-powered digital pathology, bridging the gap between biomarker development and clinical diagnostics. By leveraging their AI technology, MindPeak empowers labs to extract actionable insights from HE, IHC, and IF tissue images, facilitating both routine diagnostics and the clinical application of new biomarkers. More details can be found at MindPeak or on their LinkedIn page.

Conclusion

The collaboration between Revolune and MindPeak represents a thought-provoking stride towards resolving the complexities associated with spatial biology methodologies. With the unveiling of their streamlined approach at AACR 2026, they set the stage for a transformative impact on cancer research and beyond. Explaining the importance of such advancements, Florian Leiss states, "Our unified efforts are not just about technical integration; they are about reimagining how researchers can engage with spatial biology to unlock novel insights faster and more effectively than ever before."